Conference
792O A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)
Authors
Chi KN; Taavitsainen S; Iqbal N; Ferrario C; Ong M; Wadhwa D; Hotte SJ; Lo G; Tran B; Azad A
Volume
29
Pagination
pp. viii271-viii272
Publisher
Elsevier
Publication Date
October 1, 2018
DOI
10.1093/annonc/mdy284.001
Conference proceedings
Annals of Oncology
ISSN
0923-7534